Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age

Table 3 Comparison of test positivity rates and recommended follow-up procedures based on CRC-446 (<0.23 ug/ml CAEs) and FIT.

Age	Actual CRC-446 test positivity (% by decade) for SDCL controls (<0.23 ug/ml)	Theoretical CRC-446 positivity (incremental % by decade¹) for SDCL controls (y = 0.65x-15.8)	Actual Bioserve CRC positivity (% by decade using <0.23 ug/ml)	Estimated follow-up colonoscopies per decade based on CRC-446 test³	Estimated follow-up colonoscopies per decade based on biennial FIT⁴	Expected incidence from initial 100,000⁶	CRC-446 test estimated CRC detections⁷	FIT test estimated detections⁸
<50	12.3	10²	88.2	10,000	0	250	220	132
50-59	21.7	6.5	81.8	6,500	50,000	695	569	417
60-69	26.8	6.5	78.7	6,500	50,000	1684	1326	1010
70-79	32.3	6.5	85.3	6,500	50,000	2824	2409	1694
(Average) Total			(83.5)	30,000	150,000	5453	4523	3254

¹Based on equation y = 0.65x-15.8 fitted to SDCL control data per decade falling below CRC-446 levels of 0.23 ug/ml.
²First CRC-446 test positivity (adjusted to mean of age 30 to 50).
³Note that number of positive CRC-446 tests is independent of testing frequency. Values shown are for per decade cumulative risk and assume all CRC-446 positive subjects have colonoscopy.
⁴Based on performing one FIT test every two years with 10% positivity rate (assuming all FIT positive subjects have colonoscopy).
⁶Based on the probability of developing cancer by decade of life (2009 Canadian Cancer Stats).
⁷Based on reported Bioserve CRC decade-specific positivity rates.
⁸Based on an average sensitivity of 60% per decade.

ISSN: 1471-230X